Navigation Links
Cell Press launches a new open-access journal, Cell Reports

Cell Press reinforces its commitment to provide a broad range of publishing options for the life sciences community with the inaugural issue of a new open-access journal: Cell Reports. Since the announcement in August, after 6 months of hard work on the part of our authors, reviewers, and editorial board members as well as our own editorial and production teams, the first issue is available online today, January 26, 2011, with eight exciting papers on topics ranging from evolutionary biology to immunology.

"We are thrilled to add Cell Reports to the Cell Press family of journals, giving choice to our authors and readers and providing a new avenue for communicating cutting-edge science." said Dr. Emilie Marcus, CEO of Cell Press. "Cell Reports brings all the features scientists have come to expect from Cell Pressexciting science, highest quality content, editorial responsiveness, and rapid publicationtogether with a broad biological scope, a short report format, and an open-access business model."

Leading the Cell Reports editorial team is Dr. Boyana Konforti, who brings a wealth of experience from a successful research career and over 13 years as a professional editor. Support from Cell Press editors as well as an actively engaged editorial board ensures broad expertise across an extensive range of topics. With a focus on concise, provocative stories and a professional approach to the entire publication process, Cell Reports will make a distinctive contribution to open-access publishing.

The launch of Cell Reports is the next step in Cell Press's ongoing dedication to serving the scientific community. Cell Press has always placed a high priority on enabling authors to disseminate published research widely and easily and offers a variety of options to make content universally accessible. The Cell Press open-archive policy, enacted in 2005, allows readers to access all online research journal content free of charge from 12 months after publication. This policy now provides a resource of over 24,000 articles that are freely available online. Newly-published featured articles are also available online at no charge on a monthly basis. On behalf of authors, Cell Press has voluntarily deposited over 7,200 of the total 84,863 Elsevier contribution of research papers into PubMed Central databases over the past 5 years. Cell Press continues to partner proactively with institutions, government agencies, and funding bodies to facilitate access to research. Cell Press and Elsevier also participate in a wide range of worldwide initiatives to provide low-cost or free access to scientific information to teachers, healthcare patients and providers, as well as researchers with limited resources. In addition, subscribing libraries are able to offer free access to walk-in users.

Through Cell Reports, Cell Press is happy to provide authors with the option to publish in a prestigious journal with immediate open access. Authors can choose to publish their work under one of two Creative Commons licenses, one of which is the most liberal available. Cell Press and Elsevier share an ongoing commitment to promote access to the scientific literature and to support a broad range of sustainable publishing models.

Contact: Elisabeth (Lisa) Lyons
Cell Press

Related biology news :

1. Tiny crooners: Male house mice sing songs to impress the girls
2. Ingenuity Systems iReport Now Available: Fast, Accurate, Interactive Report for Gene Expression Data
3. Deep brain stimulation shows promising results for unipolar and bipolar depression
4. Yale scientist wins inaugural ASBMB award for her work on regulation of gene expression
5. Study examines how diving marine mammals manage decompression
6. Press registration opens for American Chemical Society National Meeting & Exposition
7. Grafting of human spinal stem cells into ALS rats best with immunosuppressant combination
8. Bikers warning! EPO hits blood vessels to raise blood pressure in the brain
9. ADFLOW Health Networks to Provide Blood Pressure Screening Centers at Rite Aid Pharmacies Nationwide
10. Mental illness: Probing the causes of schizophrenia, depression and anxiety
11. Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients
Post Your Comments:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: